Royal Marsden NHS Foundation Trust: Patients With a Form of Advanced Lung Cancer Lived 56 Per Cent Longer Without Their Disease Progressing After Receiving Radiotherapy in Addition to Standard Treatment
October 27, 2026
October 27, 2026
LONDON, England, Oct. 27 -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
Patients with a form of advanced lung cancer lived 56 per cent longer without their disease progressing after receiving radiotherapy in addition to standard treatment
Primary results from the SARON trial found the addition of radiotherapy to standard treatment plans improved progression-free survival by five months
26 October . . .
* * *
Patients with a form of advanced lung cancer lived 56 per cent longer without their disease progressing after receiving radiotherapy in addition to standard treatment
Primary results from the SARON trial found the addition of radiotherapy to standard treatment plans improved progression-free survival by five months
26 October . . .